Clinical Trial Update: Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating safety and efficacy of Torisel combined with Liposomal Doxorubicin for recurrent sarcoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sarcoma

Drugs mentioned

• Torisel (Temsirolimus)
• liposomal doxorubicin (doxorubicin liposomal)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Sarcoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-03-11